Dimitri F. Dimitriou, MSC, Chief Executive Officer of ImmuPharma is talking about the recently closed deal between ImmuPharma and Avion Pharmaceuticals.

ImmuPharma announced a deal with Avion Pharmaceuticals about a month ago to have the exclusivity in the US. Up to 25 million is funded by Avion Pharmaceuticals which is very good for the investment case. The deal will be closed after the patent will be received.

Avion Pharmaceuticals is a special US company based in Atlanta which has been growing very fast (about +50% last year). ImmuPharma also negotiates about similar dials on the other markets both in Europe and also Asia.